Key Takeaways GILD's HIV growth is driven by Biktarvy and Descovy, with Yeztugo becoming the first twice-yearly PrEP option.GILD's injectable lenacapavir strengthens prevention as Truvada faces generic competitionGILD's bictegravir-lenacapavir single-tablet regimen met phase III endpoints, supporting regulatory filings.Gilead Sciences, Inc. (GILD) has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy and Descovy. Biktarvy sales and Descovy for pre-exposure prophylaxis (PrEP) have fuel ...